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A~traet--The antineoplastic drug Adriamycin is administered by short term i.v. infusion. The drug is 
noted for its acute and chronic cardiotoxieity in addition to its toxicity on the bone marrow and gut. A 
physiological flow model and computer program, which contains a subprogram for continuous infusion 
of a drug, was used to simulate the distribution of Adriamycin during infusion in heart, bone marrow, 
gut, kidney, muscle, skin, liver and bile. Simulations were carried out for 1, 2, 5, 10 and 20 min of infusion. 
Computations were made for the concentration f drug in these organs as a function of time over a total 
period of 48 min. Simulations showed the heart and kidney would contain high concentrations of drug 
during infusion which rapidly declined upon cessation of infusion. Bone marrow and gut showed a less 
rapid accumulation and decline. Muscle and skin showed even a slower accumulation and decline. 
Simulations also showed the effect of altering the rate of infusion on the concentration i  the liver and 
excretion in the bile. 
1. INTRODUCTION 
Adriamycin isan antineoplastic drug which is noted for its cardiotoxicity in addition to its toxicity 
on the bone marrow and the gut. There can be an acute cardiotoxicity ofarrythmias and a delayed 
toxicity similar to congestive heart failure., Because of its toxicity, Adriamycin is administered not 
by bolus injections, but by short term infusion. 
Tissue concentrations of the drug vary depending on the rate of blood flow to the organ and 
the tissue-to-plasma distribution ratio, as well as the concentration f the drug in the plasma. The 
concentration i  the plasma is a dynamic function of the infusion rate and differential rates of 
uptake by tissues. In the past, the kinetics of infusion have been described by polyexponential 
equations and abstract compartments [1]. In view of the potential problem with toxicity, it would 
be very useful to have some means to determine the changing concentrations of drug in crucial 
tissue regions during and after its administration. To aid in this determination, a set of computer 
programs has been developed which are based on physiological function and flow rates, and which 
simulate the distribution of Adriamycin to various tissue regions and its elimination by excretion 
in the bile. 
These programs were adapted from a physiological flow model that was developed for the 
distribution and elimination of warfarin in the bile of the rat [2]. The simulation was extended and 
validated for Adriamycin in the rat [3]. In addition to bolus injections, the program can handle 
continuous infusion of a drug. This is important since Adriamycin isusually administered by short 
term infusion. The purpose of this report is to describe the results of numerical simulations of the 
effect of varying the rate of infusion of Adriamycin on the calculated concentration f the drug 
in various organs in the rat using a physiological flow model. 
2. METHODS 
2.1. Mathematical model 
A mathematical model was developed using a physiological flow model which included organ 
mass or volume, blood flow to the organs and tissue to plasma partition ratios [3]. Organ volumes 
or mass were computed using allometric equations of the following form: 
organ volume Y = aM b, 
tA preliminary report of this research was presented at the Federation of American Societies of Experimental Biology 
Meetings, St. Louis (April 1986). Fed. Abstr. 45(3), 207 (1986). 
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in which Y is an anatomical variable, M is the mass of the body and a and b are constants which 
have been reported for different organs. The following volumes (ml) were calculated for a 234 g 
rat: plasma, 10.45; muscle, 117.0; gut, 12.5; kidneys, 2.15; liver, 9.6; skin, 38.8; and marrow, 2.5. 
Allometric equations are useful in scaling up experimental studies for animals of different weights, 
and from laboratory animals to humans [4, 5]. Blood flows to the organs were determined also 
using allometric equations of the same form. The computed flows (ml/min) used in the model for 
a 234 g rat were: muscle, 3.45; gut, 6.08; kidney, 5.75; liver, 7.46; skin, 0.28 and bone marrow, 0.64. 
The concentration f drug within each organ or tissue region was assumed to be uniform as in 
a stirred tank reactor. Separate differential equations are used for computing the concentration f
drug in each organ as a function of time; an algebraic equation was used to compute the 
concentration of the drug in the heart. The differential equations in verbal equivalents can be 
represented as follows: 
[the rate of ] I rate of inflow I Irate of outflow ] [- rate of metabolism ] 
uptake of = of drug to - of drug from - [ and/or elimination 
a drug an organ the organ l_ by that organ 
2.2. Animals studies 
The basic model has been verified in the rat. In brief, the procedure used ~4C-Adriamycin which 
was obtained from the National Cancer Institute. The drug was diluted with non-radioactive 
Adriamycin for i.v. injection over a period of 2 min into anesthetized male Sprague-Dawley rats. 
Adriamycin is excreted primarily in the bile. The bile flow rate was 25 #1/min. Bile samples were 
collected from the cannulated duct for 120-150 min to measure the rate of excretion of the drug. 
These values were used in testing the model. Blood samples were obtained from the snipped tail 
at frequent intervals. These values also were used in validating the model. Tissue samples were 
obtained at the end of the experiment for the determinations of tissue to plasma partition ratios 
for the model parameters used in the present report: muscle, 4.27; gut, 17.87; kidney, 25.86; 
liver, 36.60; skin, 5.75; marrow, 47.74; and heart, 32.17. The kinetic parameters for the elimination 
rates were determined from the concentrations of drug in bile and plasma using a weighted 
least squares regression analysis. The values used were: Vmax = 10.25nmole x min -j g-~ and 
Km= 125 nmole x g-~. 
2.3. Computer program 
The simulation was implemented in FORTRAN to compute the concentration f drug in each 
organ in the model as a function of time [3]. The program can handle a single bolus injection of 
a drug, repeated (up to 10) bolus injections, as well as continuous infusion. Simulated continuous 
infusions (of 1, 2, 5, 10 and 20 min) were used exclusively for the present report for a total time 
of analysis of 48 min. It is possible in the programs to combine infusion with injections. 
The computed ata for each organ and for each time of infusion (1, 2, 5, 10 and 20 min) were 
merged using SAS (statistical analysis ystems) procedures and stored as merged ata in a SAS 
Systems Library. The merged data were printed using SAS PROC PRINT and plotted on a 
CalComp 1077 precision plotter using SAS PROC GPLOT. 
3. RESULTS 
3.1. Concentration of Adriamycin in plasma 
In the example shown (Fig. 1) the dose of Adriamycin was (10 mg/kg) for an animal weighing 
0.234 kg. The computed volume of plasma (Vp) was 10.44 ml; thus, the calculated concentration 
of Adriamycin in the plasma t zero time, following a bolus injection, would be 224.1 nmole ml-~. 
The calculated concentrations in the plasma at the end of infusion for 1, 2, 5, 10 and 20 min of 
infusion are presented in Table 1 along with the percentage of the calculated concentration for 
uniform distribution in the plasma at zero time. Note that for infusion times greater than 2 min, 
the maximum plasma concentration is almost exactly proportional to the rate of infusion. 
Adriamycin is noted for its rapid disappearance from the plasma and its rapid distribution to 
tissues. This behavior is reflected in Fig. 1, which shows the computed concentration f Adriamycin 
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Fig. 1. Simulated concentration of Adriamycin in plasma during continuous infusion. The concentration 
of Adriamycin in the different organs in the model were computed for 1, 2, 5, 10 and 20 min ofi.v, infusion 
and stored on disk. The computed concentrations (nmole/ml - t )  in plasma for the different durations 
of infusion were merged and plotted using SAS PROC GPLOT using the splin¢ option to provide the 
solid lines. For clarity the spline option was not used for the concentrations for 2 rain (<>) of  infusion. 
in the plasma after infusions of the same total amount over periods of I, 2, 5, 10 and 20 min 
duration. The concentration of Adriamycin in the plasma increases throughout the course of 
infusion. The rate of increase in concentration depends on the rate of infusion. At the lowest rate 
(20 min duration), a near steady state condition is reached in which the rate of loss from the plasma 
is nearly equal to the rate of infusion. Following the infusion, there is a rapid decrease in the 
concentration of drug in the plasma which is a result, in part, of the low degree of binding by 
plasma proteins and the high degree of binding by tissue components. 
3.2. Concentration in heart and kidney 
The concentration profiles of drugs in various tissues is a function of a number of factors, such 
as the concentration of drug in the plasma, the rate of blood flow to the tissues, and the 
tissue-to-plasma p rtition ratio. The shape of the profiles of the concentrations of Adriamycin in 
the heart (Fig. 2) and kidney (not shown) are very similar to that of the plasma but differ markedly 
from the profiles in other organs. These two organs with very high blood perfusion rates have a 
Table 1. The calculated concentration f Adriamycin in the plasma 
at the end of infusion for different imes 
Time of infusion Conc. in plasma Percent of 0 min' 
(min) (nmole/ml-t ) (%) 
(P 224.1 100 
I 142.4 64 
2 101.7 45 
5 40.7 18 
10 20.3 9 
20 10.2 5 
'Assuming instantaneous and uniform distribution in the plasma. 
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Table 2. Comparison of peak concentrations and time at different rates of infusion of Adriamycin 
865 
Duration of 
infusion 
(min) 
Tissue a Tissue 
Plasma Muscle Kidney Liver Bile Gut Marrow Heart Skin 
1 142 8.7 (15) b 461(2) 35.2(6) 1030(12) 109(4) 79 (19)  4581(I) 2.8(>48) 
2 102 8.7 (16) 455 (3) 35.2 (7) 1031 (13) 109 (5) 79 (20) 3272 (1) 2.8 (> 48) 
5 41 8.7 (18) 391 (5) 34.8 (9) 1022 (15) 108 (7) 79 (22) 1764 (4) 2.8 (> 48) 
10 20 8.7 (21) 309 (10) 33.6 (12) 993 (18) 105 (11) 79 (22) 1038 (9) 2.8 (>48) 
20 10 8.6 (27) 204 (20) 30.0 (20) 910 (26) 93 (20) 78 (29) 601 (19) 2.8 (> 48) 
"Concentration ( mole/ml- s). 
bThe numbers in parentheses indicate the time of the peak (rain) as determined from the computer printout of the data. 
distinct concentration profile which is characterized by a peak which is reached uring infusion, 
and then followed by a sharp drop in concentration when infusion is discontinued. As for the 
plasma, halving the rate of infusion halves the peak concentration reached in the heart. 
When infusion stops, Adriamycin is quickly transported out of the heart and kidney and into 
regions with higher binding ratios and slower rates of blood flow. In contrast, for example, the 
concentration in the gut (Fig. 2) and bone marrow (Fig. 2) reach a peak with a moderate decline 
when infusion is discontinued. 
3.3. Concentration i gut and bone marrow 
The toxicity of a drug in an organ can be related to various chemical and/or biochemical factors 
which differ for different organs depending upon their specialized functions. The gut and bone 
marrow are both noted for their toxic reactions to a variety of anti-neoplastic agents. In both of 
these tissues, the Adriamycin infusion causes a gradual increase in concentration followed by a 
gradual decline (Fig. 2). The peak concentrations occur well after the infusion has ceased. This 
behavior eflects the redistribution of the drug stored in other areas during the infusion. Note, 
unlike the plasma nd heart peaks, that the peak concentrations i  the gut and bone marrow are 
not greatly affected by the infusion rates studied here. The infusion rate would have to have been 
reduced by an order of magnitude to affect he concentrations in the bone marrow. 
The peak concentrations i  the gut were attained earlier than in the marrow (Table 2), primarily 
because of the more rapid blood flow to the gut. The decrease in concentration in the gut was also 
faster than in the bone marrow for the same reason. 
3.4. Concentration i muscle and skin 
The muscle and skin are not special sites of toxicity for Adriamycin but, since they constitute 
a rather large fraction of the body mass, they store a significant fraction of the drug and are 
therefore included in the model. Table 2 shows the peak concentrations in these tissues and the 
time of the peak. The concentration profiles of the muscle resembles that of the bile (Fig. 3). The 
skin is unusual with a slow build-up that has not peaked at 48 min, presumably because the slow 
rate of blood flow to this tissue delays the attainment of the peak concentration. It represents a 
reservoir of Adriamycin that is returned to the plasma over an extended period. 
3.5. Excretion of Adriamycin 
Adriamycin is taken up by the liver, from which it is excreted in the bile. Figure 3 shows the 
time course of concentration i  the liver. Note the difference in pattern from that shown for the 
heart. The profile in the liver more nearly resembles that of the gut which has a similar ratio of 
binding capacity to the blood perfusion rate. The profile for the concentration i  the bile peaks 
somewhat later than that of the liver (Fig. 3), but note that the bile concentrations are 30 times 
higher than the average for the liver. This makes it clear that the drug is not distributed uniformly 
on a microscale in the liver. 
4. DISCUSSION 
Drug distribution and elimination has been described by polyexponential models [1] and 
physiological flow models [2-4]. The polyexponential models use rate constants for the distribution 
of a drug in abstract compartments. On the other hand, the physiological flow model describes 
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the kinetics of distribution of a drug into anatomical compartments using anatomical, phys- 
iological, and pharmacological parameters. A previous report has shown some relationships 
between these two models [6]. The physiological f ow model can be reduced to a polyexponential 
model but not vice versa without providing additional information which in essence converts it to 
a physiological f ow model. 
Formulae have been presented for continuous infusion of a drug using polyexponential models 
[1]. In the present work, continuous infusion is shown for a physiological f ow model. 
Adriamycin is usually administered tohumans in not less than 3-5 min. Our simulations included 
more rapid (1 and 2 min) and less rapid (10 and 20 min) infusions which provide some theoretical 
information which can be of practical value. The simulations show different concentration profiles. 
The heart and kidney showed sharp concentration peaks. The present simulations how that 
reducing the rate of infusion for the same total dose reduces the concentration, particularly in 
rapidly perfused tissues uch as the heart and the kidney. One could conclude this intuitively, but 
simulations using anatomic and physiologic parameters provides a more quantitative picture of the 
magnitude and the kinetics of changes which would occur with different rates of infusion. 
Furthermore, one might not as easily predict hat peak concentrations in slowly perfused regions 
such as bone marrow, are not greatly affected by drug infusion rates. 
Adriamycin is a drug noted for its reactivity forming free radicals which can react with DNA 
[7], and other cell fractions [8-10], and for its conspicuous organotoxicity. Elevated concentrations 
of the drug in a tissue could result in toxicity resulting from the higher concentration of drug and 
its highly reactive products. The model [3] also includes a compartment for almost irreversibly 
bound drug which can incorporate the covalent bonding. The present analysis is primarily kinetic 
rather than mechanistic. 
The physiological f ow model has additional advantages [5, 11] beyond the ability to predict 
tissue concentrations. The interlinking of the equations in the model permits one to integrate 
anatomical, biochemical, physiological and organ pathology into a comprehensive picture which 
can be of value to the theoretical pharmacologist, the clinical pharmacologist and the oncologist. 
For example, the model and program can be adapted to cope with organ pathology such as liver 
disease, which is especially important for drugs metabolized in the liver and excreted in the bile 
[12]. Although the present report does not include the effects of liver damage on the kinetics and 
distribution of Adriamycin, the feasibility of including such effects has been described previously 
[ll, 12]. 
Although physiological flow models may appear excessively complex, they are really just a 
combination of relatively simple parts. Current computers and numerical methods can cope with 
these mathematical combinations. In.cancer chemotherapy, such models can help present a clearer 
picture of what actually occurs in the tissues and organs. 
Physiological f ow models also can be scaled up from experimental nimals to man [5]. Lee et 
al. [13] have reported a number of examples in which models have been successfully applied to 
human therapy. The combined understanding of anatomy, physiology and pathology incorporated 
into a comprehensive pharmacokinetic model could enhance the safety of cancer chemotherapy 
with toxic drugs. 
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